Challenge A therapeutics company struggled to use public omics datasets to guide critical portfolio decisions, such as identifying patient population sizes for different targets, evaluating opportunities for indication expansion to determine where their therapy might be most effective, and selecting the most appropriate cell lines for in vitro or PDX experiments. The datasets were scattered… Read More » Streamlining Omics Data Analysis for Faster Decision-Making